80 related articles for article (PubMed ID: 1348452)
1. Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
Cutler NR; Reines SA; McLean LF; Sramek JJ; Porras AG; Hand EL
Clin Pharmacokinet; 1992 Mar; 22(3):223-30. PubMed ID: 1348452
[TBL] [Abstract][Full Text] [Related]
2. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Lieberman A; Chin L; Baumann G
Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
[TBL] [Abstract][Full Text] [Related]
3. Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC.
Ishikawa T; Watanabe Y; Takayama K; Endo H; Matsumoto M
Int J Pharm; 2000 Jul; 202(1-2):173-8. PubMed ID: 10915941
[TBL] [Abstract][Full Text] [Related]
4. Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).
Ahlskog JE; Muenter MD; Bailey PA; Stevens PM
Arch Neurol; 1992 May; 49(5):560-8. PubMed ID: 1580821
[TBL] [Abstract][Full Text] [Related]
5. Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation.
Miyazaki S; Kawasaki N; Nakamura T; Iwatsu M; Hou WM; Attwood D
Int J Pharm; 2000 Aug; 204(1-2):127-32. PubMed ID: 11011995
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
Tompson DJ; Vearer D
Clin Ther; 2007 Dec; 29(12):2654-66. PubMed ID: 18201581
[TBL] [Abstract][Full Text] [Related]
7. Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
Koller WC; Block GA; Ahlskog JE; Ahrens S; Cedarbaum JM; Cyhan G; Goetz CG; LeWitt PA; Liss C; McLean L
Clin Neuropharmacol; 1991 Aug; 14(4):322-9. PubMed ID: 1913699
[TBL] [Abstract][Full Text] [Related]
8. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation.
Huang YB; Tsai YH; Yang WC; Chang JS; Wu PC; Takayama K
Eur J Pharm Biopharm; 2004 Nov; 58(3):607-14. PubMed ID: 15451535
[TBL] [Abstract][Full Text] [Related]
9. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Cedarbaum JM; Clark M; Toy LH; Green-Parsons A
Mov Disord; 1990; 5(4):298-303. PubMed ID: 1979657
[TBL] [Abstract][Full Text] [Related]
10. In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets.
Ghimire M; Hodges LA; Band J; O'Mahony B; McInnes FJ; Mullen AB; Stevens HN
J Control Release; 2010 Oct; 147(1):70-5. PubMed ID: 20600400
[TBL] [Abstract][Full Text] [Related]
11. The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation.
McConville JT; Ross AC; Chambers AR; Smith G; Florence AJ; Stevens HN
Eur J Pharm Biopharm; 2004 May; 57(3):541-9. PubMed ID: 15093604
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
13. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
[TBL] [Abstract][Full Text] [Related]
14. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
15. Poor tolerability of MK-458.
Cutler NR; Sramek JJ; Block GA
Arch Neurol; 1993 Sep; 50(9):896. PubMed ID: 8363442
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
17. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
Cao QR; Choi YW; Cui JH; Lee BJ
J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
[TBL] [Abstract][Full Text] [Related]
18. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of khaya gum as a directly compressible matrix system for controlled release.
Odeku OA; Fell JT
J Pharm Pharmacol; 2004 Nov; 56(11):1365-70. PubMed ID: 15525442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
